210 related articles for article (PubMed ID: 14576044)
1. Novel concatameric heparin-binding peptides reverse heparin and low-molecular-weight heparin anticoagulant activities in patient plasma in vitro and in rats in vivo.
Schick BP; Maslow D; Moshinski A; San Antonio JD
Blood; 2004 Feb; 103(4):1356-63. PubMed ID: 14576044
[TBL] [Abstract][Full Text] [Related]
2. Thrombin generation assays are superior to traditional tests in assessing anticoagulation reversal in vitro.
Gatt A; van Veen JJ; Woolley AM; Kitchen S; Cooper P; Makris M
Thromb Haemost; 2008 Aug; 100(2):350-5. PubMed ID: 18690358
[TBL] [Abstract][Full Text] [Related]
3. Assay-Based Differentiation in the Neutralization Profile of Unfractionated Heparin, Enoxaparin, and Fondaparinux by Andexanet Alfa.
Siddiqui F; Tafur A; Bontekoe E; Iqbal O; Jeske W; Mehrotra S; Hoppensteadt D; Ramacciotti E; Fareed J
Clin Appl Thromb Hemost; 2020; 26():1076029619895120. PubMed ID: 31914798
[TBL] [Abstract][Full Text] [Related]
4. Low molecular weight heparin inhibits plasma thrombin generation via direct targeting of factor IXa: contribution of the serpin-independent mechanism.
Buyue Y; Misenheimer TM; Sheehan JP
J Thromb Haemost; 2012 Oct; 10(10):2086-98. PubMed ID: 22905983
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo characterization of a reversible synthetic heparin analog.
Whelihan MF; Cooley B; Xu Y; Pawlinski R; Liu J; Key NS
Thromb Res; 2016 Feb; 138():121-129. PubMed ID: 26709038
[TBL] [Abstract][Full Text] [Related]
6. Low molecular weight protamine (LMWP) as nontoxic heparin/low molecular weight heparin antidote (II): in vitro evaluation of efficacy and toxicity.
Chang LC; Liang JF; Lee HF; Lee LM; Yang VC
AAPS PharmSci; 2001; 3(3):E18. PubMed ID: 11741269
[TBL] [Abstract][Full Text] [Related]
7. Differential Neutralization of Unfractionated Heparin and Enoxaparin by Andexanet Alfa.
Lewis J; Iqbal O; Jeske W; Hoppensteadt D; Siddiqui F; Fareed J
Clin Appl Thromb Hemost; 2022; 28():10760296221099934. PubMed ID: 35535398
[TBL] [Abstract][Full Text] [Related]
8. Antithrombin binding of low molecular weight heparins and inhibition of factor Xa.
Lin P; Sinha U; Betz A
Biochim Biophys Acta; 2001 Apr; 1526(1):105-13. PubMed ID: 11287128
[TBL] [Abstract][Full Text] [Related]
9. Anti-metastatic effect of a non-anticoagulant low-molecular-weight heparin versus the standard low-molecular-weight heparin, enoxaparin.
Mousa SA; Linhardt R; Francis JL; Amirkhosravi A
Thromb Haemost; 2006 Dec; 96(6):816-21. PubMed ID: 17139378
[TBL] [Abstract][Full Text] [Related]
10. Protamine neutralisation of low molecular weight heparins and their oligosaccharide components.
Schroeder M; Hogwood J; Gray E; Mulloy B; Hackett AM; Johansen KB
Anal Bioanal Chem; 2011 Jan; 399(2):763-71. PubMed ID: 20922518
[TBL] [Abstract][Full Text] [Related]
11. Effect of nonspecific binding to plasma proteins on the antithrombin activities of unfractionated heparin, low-molecular-weight heparin, and dermatan sulfate.
Cosmi B; Fredenburgh JC; Rischke J; Hirsh J; Young E; Weitz JI
Circulation; 1997 Jan; 95(1):118-24. PubMed ID: 8994426
[TBL] [Abstract][Full Text] [Related]
12. Preparation and evaluation a new generation of low molecular weight heparin.
Zhao D; Sang Q; Cui H
Biomed Pharmacother; 2016 Apr; 79():194-200. PubMed ID: 27044828
[TBL] [Abstract][Full Text] [Related]
13. A [+18RGD] protamine variant for nontoxic and effective reversal of conventional heparin and low-molecular-weight heparin anticoagulation.
Wakefield TW; Andrews PC; Wrobleski SK; Kadell AM; Tejwani S; Hulin MS; Stanley JC
J Surg Res; 1996 Jun; 63(1):280-6. PubMed ID: 8661211
[TBL] [Abstract][Full Text] [Related]
14. Novel design of peptides to reverse the anticoagulant activities of heparin and other glycosaminoglycans.
Schick BP; Gradowski JF; San Antonio JD; Martinez J
Thromb Haemost; 2001 Mar; 85(3):482-7. PubMed ID: 11307819
[TBL] [Abstract][Full Text] [Related]
15. Heparin-Binding Copolymer as a Complete Antidote for Low-Molecular-Weight Heparins in Rats.
Kalaska B; Miklosz J; Kamiński K; Swieton J; Jakimczuk A; Yusa SI; Pawlak D; Nowakowska M; Szczubiałka K; Mogielnicki A
J Pharmacol Exp Ther; 2020 Apr; 373(1):51-61. PubMed ID: 31937564
[TBL] [Abstract][Full Text] [Related]
16. In vitro comparison of the novel, dual-acting FIIa/FXa-inhibitor EP217609C101, unfractionated heparin, enoxaparin, and fondaparinux in preventing cardiac catheter thrombosis.
Kaeberich A; Raaz U; Vogt A; Maedgefessel L; Neuhart E; Krezel C; Drouget L; Hauroeder B; Buerke M; Werdan K; Schlitt A
J Thromb Thrombolysis; 2014; 37(2):118-30. PubMed ID: 23821043
[TBL] [Abstract][Full Text] [Related]
17. Histones Differentially Modulate the Anticoagulant and Profibrinolytic Activities of Heparin, Heparin Derivatives, and Dabigatran.
Ammollo CT; Semeraro N; Carratù MR; Colucci M; Semeraro F
J Pharmacol Exp Ther; 2016 Feb; 356(2):305-13. PubMed ID: 26578266
[TBL] [Abstract][Full Text] [Related]
18. Heparin-induced thrombocytopenia: a stoichiometry-based model to explain the differing immunogenicities of unfractionated heparin, low-molecular-weight heparin, and fondaparinux in different clinical settings.
Greinacher A; Alban S; Omer-Adam MA; Weitschies W; Warkentin TE
Thromb Res; 2008; 122(2):211-20. PubMed ID: 18262226
[TBL] [Abstract][Full Text] [Related]
19. In vitro comparison of the effect of heparin, enoxaparin and fondaparinux on tests of coagulation.
Linkins LA; Julian JA; Rischke J; Hirsh J; Weitz JI
Thromb Res; 2002 Sep; 107(5):241-4. PubMed ID: 12479885
[TBL] [Abstract][Full Text] [Related]
20. The effect of subcutaneous injection of unfractionated and low molecular weight heparin on thrombin generation in platelet rich plasma--a study in human volunteers.
Bendetowicz AV; Kai H; Knebel R; Caplain H; Hemker HC; Lindhout T; Béguin S
Thromb Haemost; 1994 Nov; 72(5):705-12. PubMed ID: 7900078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]